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Background: Patients with nephrotic syndrome are at an increased risk of thromboembolic events (TEs). However,
this association has not been thoroughly investigated in adult patients with idiopathic membranous nephropathy
(IMN).
Methods: A retrospective analysis of all 101 consecutive adult patients with MN diagnosed at our centre during
1995 to 2008 was performed. Pertinent data including thromboembolic events and the risk factors for TEs were
recorded.
Results: The cohort was followed for 7.2 ± 3 years. Out of 78 patients with IMN, 15 (19.2%) had at least one TE. No
TEs occurred six months after diagnosis. The incidence of TEs in the first 6 months of diagnosis was 7.69% (95%CI,
2.5-17.0) and all patients except one had venous TEs. At the time of diagnosis of MN, the patients with TEs had
lower serum albumin (1.9 ± 0.5 vs. 2.4 ± 0.4 g/dl, TE vs. no TE; p < 0.01) and greater serum cholesterol (414 ± 124 vs.
317 ± 108 mg/dl, TE vs. no TE; p = 0.01) and 24-h proteinuria (10.7 ± 3 vs. 7.1 ± 4 g, TE vs. no TE; p < 0.01). Multivariate
logistic regression adjusted for age, sex, cholesterol and creatinine revealed, an odds ratio of 0.8 (95% CI 0.7 – 0.96;
p = 0.01) for every one g/dl increase in baseline serum albumin and, an odds ratio of 1.3 (95% CI 1.05-1.58; p = 0.01)
for one gram increase in 24-h proteinuria, for TEs.
Conclusions: Our study finding confirms IMN as a prothrombotic state particularly in the first six months of
diagnosis. Proteinuria, in addition to hypoalbuminemia, is a risk factor for TEs. These results have important
implications for clinical care of patients with IMN, particularly with regards to initiation and duration of prophylactic
anticoagulation.
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Membranous nephropathy (MN) is the most common
cause of nephrotic syndrome in Caucasian adults [1].
Patients with nephrotic syndrome are at increased risk
of thromboembolic events (TEs) among whom, patients
with membranous nephropathy are at an exaggerated
risk [2-4]. In 1980s, few case series found that the
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reproduction in any medium, provided the orpatients with MN [5-8]. Subsequently, in early 1990s,
Bellomo et al. in a letter to the editor reported that a
significantly greater proportion of MN patients with
thromboembolic events had nephrotic syndrome with
serum albumin of less than 25 g/l as compared to pa-
tients without thromboembolic events. Based on these
published data, it is widely believed that such patients
should be prophylactically anticoagulated if serum albu-
min is less than 20 – 25 g/l [9]. A recent large retros-
pective study found an eight times higher absolute risk
of venous TEs in patients with nephrotic syndrome and
the ratio of proteinuria to serum albumin, not serumLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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patients with nephrotic syndrome of varied causes [4].
However, the IMN patients were not specifically the
focus of investigation.
Investigators have suggested that randomized clinical
trials should be conducted to identify whom to adminis-
ter prophylactic anticoagulation, for how long and in to
determine whether anti-coagulation in adult MN
patients would improve overall outcomes [10]. However,
for trials involving idiopathic MN (IMN) patients key in-
formation that may help to design such studies are still
lacking, in particular with regards to the timing of
thromboembolic events with respect to the diagnosis,
their relationship to disease activity and the risk factors.
Moreover, the conditions associated with MN (secon-
dary MN) such as lupus [11], human immunodeficiency
viral infection [12] or malignancies [13] are themselves
pro-thrombotic and per se require anti-coagulation irre-
spective of the presence of nephrotic syndrome. This
means that these MN patients, if they have other indica-
tions for anticoagulation, may be not eligible to be ran-
domised to anticoagulation.
Though the pathophysiological mechanisms of throm-
boembolic events in IMN patients are poorly understood,
one of the major underlying mechanisms for such
complication is the nephrotic syndrome with increased
urinary loss of plasma proteins such as plasminogen
(component of fibrinolytic system), factors IX, X and XII
(components of the coagulation system) and antithrom-
bin III (endogenous anticoagulant) [14-18]. The urinary
losses of such plasma proteins correlate with the degree
of proteinuria [14,16]. Therefore, we hypothesized that
the degree of proteinuria could be a risk factor for
thromboembolic events in patients with IMN. If so, this
may aid in better risk stratification of patients with IMN
with respect to TEs and anti-coagulation. To the best
of our knowledge, TEs have not been thoroughly in-
vestigated in the adult IMN patients. Therefore, we
performed a retrospective analysis of the prospectively
collected data on all consecutive biopsy-proven adult
IMN patients diagnosed at our centre (i) to characterize
the TEs (ii) to determine the timing of the thrombo-
embolic events relative to the diagnosis and (iii) to iden-




The prospectively collated computerized data of all con-
secutive biopsy-proven adult cases of membranous
nephropathy diagnosed at our centre between January
1995 and December 2010 were reviewed. Patients who
at the time of study entry (January 1995) were ≥ 18 years
of age were included. The diagnosis of nephroticsyndrome was confirmed by proteinuria of ≥ 3.5 g/day,
derived from a 24-h urine collection. All biopsies were
examined by light microscopy and direct immunofluo-
roscence (for immunoglobulin-G, -M, -A, C3, C1q).
Congo red stain was also performed on all the biopsies.
Histological diagnosis of membranous nephropathy was
made if: (i) normal basement membrane on light mi-
croscopy was associated with evidence of IgG deposits
on histochemical studies (ii) presence of basement-
membrane spikes (iii) incorporation of deposits into the
basement membrane or (iv) markedly thickened base-
ment membrane. MN was considered to be secondary if
it occurs in the setting of known secondary causes of
MN including malignancy, infections, auto-immune dis-
orders and drugs. The development of a secondary ill-
ness that is well recognized to be associated with MN
(such as malignancy) during the observation period, to
suggest a secondary cause of IMN was categorized as
secondary MN. Therefore, the patients diagnosed with
MN during the last couple of years (2007/8) of the study
period were followed up for two more years (2009/10).
All patients had age-appropriate screening for causes
of secondary MN along with serological tests includ-
ing hepatitis B, C, HIV, serum complements, serum
immunoglobulins, rheumatoid factor, serum protein
electrophoresis as well as anti-nuclear antigen (ANA),
anti-neutrophilic cytoplasmic antigen (ANCA) and anti-
glomerular basement membrane (anti-GBM) antibodies
performed which were negative.
Baseline demographics and relevant biochemical data
collected included age at presentation, sex, ethnicity,
baseline serum creatinine, serum albumin, serum choles-
terol and 24 h-urine proteinuria. Glomerular filtration
rate was estimated using the abbreviated Modification
of Diet in Renal Disease Study equation 186.3 × serum
creatinine -1.154 × age -0.203 × 0.742 (if female patient) ×
1.212 (if black). MN was considered to be active if the
patient had proteinuria of ≥ 3.5 g/day. The medical
records were also reviewed for exposure to risk factors
for thromboembolic events including major surgery, trau-
ma, malignancy, immobilization for more than 1 week
and pregnancy. History of previous thromboembolic
events was also recorded.
Diagnosis of thromboembolic events
The TEs were established by review of the aforemen-
tioned prospectively collated computerized case-notes.
The patients were considered to have had a thrombo-
embolic event if the event was clinically apparent and
confirmed by diagnostic studies. In addition, telephonic
interview was also employed to ensure that the patients,
who were identified and classified as “no thrombo-
embolic event cohort”, had no TEs during the course
of their disease. Clinical evidence of thromboembolic
Figure 1 Flow diagram showing all consecutive biopsy-proven
membranous nephropathy patients diagnosed at our centre
between January 1995 and December 2008.
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ful limbs, dyspnoea, hypoxaemia, chest pain (ischemic or
pleuritic), haemoptysis, or other features of deep vein
thrombosis or pulmonary embolism. Clinically, cerebro-
vascular event was considered to occur in the presence
of neurological symptoms and signs. Diagnostic confir-
mation included findings of doppler vascular ultraso-
nography, ventilation-perfusion scanning (V/Q scan),
computed tomography pulmonary angiography (CTPA),
and computed tomographic brain scan (CT brain). The
diagnosis of a thromboembolic event was confirmed by
using radiological criteria as per Royal society of radio-
logy and British thoracic society guidelines. Briefly, con-
sistent non-compressibility of the lower limb venous
segment on doppler ultrasound was diagnostic of deep
vein thrombosis. V/Q scan results were categorized as
high probability for pulmonary thrombosis if there were
1 or more segmental perfusion defect(s) with normal
ventilation or 2 or more large subsegmental perfusion
defects (>75% of a segment) with normal ventilation.
The finding of an intraluminal filling defect within a pul-
monary arterial vessel was considered to be confirmatory
of pulmonary embolism.
Statistical analysis
Results are expressed as mean ± standard deviation (sd)
for continuous data and as percentages for categorical
data. The significance of differences in clinical and la-
boratory data between the groups was tested by unpaired
t–test, Mann–Whitney U-test, Wilcoxon signed-rank
test, and chi-square test as appropriate. To identify risk
factors for thromboembolic events, univariable and mul-
tivariable forward logistic regression analysis was per-
formed (SPSS software version 12). The inclusion
criterion for a variable was based on the score statistic i.
e. the variable with the most significant score statistic
was added to the model. Likelihood ratio statistic and
Wald criterion was employed to exclude the variable.
Complete data sets for multivariable analysis were availa-
ble in 52 out of 62 patients (84%) in the “no TE” group
and 14 out of 15 (93%) in TE group. An exact 95% confi-
dence interval was calculated for the 6 months incidence
rate in patients who did not have a TE before or at the
time of diagnosis. All statistical analyses were two sided,




Between 1st January 1995 and 31st December 2008, a
total of 101 patients were diagnosed to have biopsy-
proven membranous nephropathy at our centre
(Figure 1). Twenty-three out of 101 patients (22.7%)
were considered to have secondary MN. The remaining78 (77.3%) were diagnosed to have idiopathic MN and
constituted the study population. Secondary causes of
MN were malignancies (lymphoma, n = 3; solid organ,
n = 3); infections (hepatitis-B, n = 3; human immunode-
ficiency virus, n = 2); auto-immune disorders (systemic
lupus erythematosus, n = 9; systemic sclerosis, n = 1; anti-
phospholipid syndrome, n = 1) and drugs (pencillamine
therapy, n = 1).
Among the 78 patients with IMN, 15 (19.2%) had at
least one episode of thromboembolic events (TE group);
the remaining 63 patients (80.8%) had no episode of
thromboembolic events (No TE group). The average age
of our entire MN cohort was 58 ± 16 years with 42 out
of 66 (63%) being male. The patients were from varied
ethnic backgrounds including Caucasians (59%), Afro-
Carribeans (16%), South-Asians (13%) and Middle-East
(12%). The cohort was followed for 7.2 ± 3 years. The
mean baseline eGFR was 65 ± 27 (ml/min per 1.73 m2)
Kumar et al. BMC Nephrology 2012, 13:107 Page 4 of 8
http://www.biomedcentral.com/1471-2369/13/107and mean serum albumin and cholesterol was 2.3± 0.4 g/dl
and 336±128 mg/dl, respectively. The average 24-h pro-
teinuria was 7.9± 3.5 g.
Treatment
Patients were commenced on immuno-supressive the-
rapy, if they continued to remain nephrotic in spite of
three months of maximal medical treatment as per
our unit’s policy. In addition, warfarin anti-coagulation
prophylaxis was commenced at the same time if the
serum albumin remained persistently below 25 g/dl. Out
of 78 patients with primary membranous nephropathy,
49 patients were immunosupressed on the treating clini-
cian’s discretion. Thirty-two (66.6%) patients were induced
in remission with oral cyclophosphamide and predni-
solone. Six with prednisolone alone, six patients were
induced with prednisolone and azathioprine, two with
prednisolone and mycophenolate mofetil and a further
three with calcineurin inhibitors (two with ciclosporin and
one with tacrolimus).
Thromboembolic events
Among 78 IMN patients, fifteen patients (19.2%) suf-
fered TE. Data was not available on one patient with TE
and hence, was excluded from further analysis (Figure 1).
The median age at presentation with a TE was 59 years
(range 22-82 yrs) and 11 out of 14 (78%) patients with
TE were male. The most commonly encountered TE
was pulmonary embolism (PE, n = 9, 64%) followed by
lower extremity deep vein thromboses (DVT, n = 3,
21%). One patient had arterial thromboembolic event in
the form of a CVA. All patients with PE presented with
shortness of breath and were noted to be hypoxic except
patient 13 (Table 1.) who presented with haemoptysis.
The patients with DVT presented with asymmetrical
swelling of calves, in addition, to pedal oedema. One pa-
tient had renal vein thrombosis (RVT) and presented
with bilateral loin pain and pedal oedema. The patient
with CVA presented with left hemiparesis. The latter pa-
tient (Table 1), a non-smoker, previously fit and well,
was diagnosed with IMN three months prior to the
onset of neurological symptoms. The diagnosis of IMN
was established on the basis of bilateral pedal edema
(four month duration), serum albumin, 2.1 g/dl, serum
cholesterol, 440 mg/dL, 24 h-proteinuria, 10.4 g/24 h
and renal biopsy findings of MN. Whilst under close fol-
low-up, he suffered from CVA and the CT scan brain
revealed a lacunar infarct in the right middle cerebral ar-
tery territory. The other battery of investigations includ-
ing blood glucose, thrombophilia screen, auto-immune
profile, CT angiogram of cranial vessels, carotid dopplers
and echocardiography were all unremarkable. Hence,
the thrombotic event was attributed to the nephrotic
syndrome.We next looked at the timing of the diagnosis of TEs
and IMN. Nine out of fourteen patients (64%) presented
with a thromboembolic event and nephrotic-range pro-
teinuria that led to the diagnosis of IMN. Out of these
nine patients, five (36%) were immediately diagnosed,
whereas four (28%) patients had TEs 2, 1, 2 and
0.5 months before the diagnosis was established. The lat-
ter group represents the cohort where the diagnosis of
nephrotic syndrome was not suspected and hence the
delay in diagnosis. Among the patients whose diagnosis
was delayed by more than 15 days, two of them suffered
from pulmonary embolism and the third patient
(Table 1.) had deep vein thrombosis. The first two
patients with PE, presented to the accident and emer-
gency department via their general practitioners (GPs)
with 1 – 2 week history of intermittent shortness of
breath and pleuritic chest pain. The third patient with
DVT presented with a 10-day history of bilateral swollen
calves via the similar route. Past medical history was un-
remarkable for all three patients. On presentation, they
were haemodynamically stable with unremarkable chest
X-ray. An emergency V/Q scan confirmed the diagnosis
of PE (Table 1, patient 1 and 2) and the diagnosis of
DVT was confirmed in the third patient via an imme-
diate lower limbs doppler ultrasound scan. The possibi-
lity of nephrotic syndrome as the underlying etiology
was not entertained and the patients were referred back
to their GPs on anti-coagulants. The persistence of
symptoms led to repeat laboratory investigations that
included serum albumin. Further investigations inclu-
ding urine dipstick analysis revealed the diagnosis. The
remaining five patients suffered VTE within six months
after the diagnosis of IMN yielding an incidence rate of
7.69% (95% confidence interval, 2.54% - 17.05%) over
6 months. These patients were not on any prophylactic
anti-coagulation. We reviewed all patients at the end of
the study period and we could not identify any patients
in our cohort with IMN who went on to develop VTEs
after six months of diagnosis of IMN whilst they were
under regular follow-up. All the patients had active MN
when they presented with thromboembolic event. All
the patients who presented with TEs were immediately
anticoagulated on confirmation of the diagnosis of TE.
Risk factors
Baseline characteristics and clinical data of patients with
idiopathic membranous nephropathy at the time of renal
biopsy i.e. at the time of diagnosis, is summarized on
Table 2. None of the patients in the TE group had
trauma, surgery, or previous history of thromboembolic
events or immobilization. The two groups (TE vs. no
TE) were similar with respect to age (57 ± 17 vs
58 ± 16 years), sex (males, 78% vs. 73%), ethnicity (Afro-
Carribeans, 14% vs. 17%), duration of follow-up (7.8 ± 3
Table 1 Patients with idiopathic membranous nephropathy with thromboembolic events*








1 68 M 1995 PE, V/Q (Pred + CycloP) 1.8, 14 - 2
2 43 M 1998 PE, V/Q (Pred + CycloP) 1.7, 14 - 1
3 82 M 1999 IleofemDVT#, US (spontaneous remission) 2.0, 12 + 6
4 58 M 2000 PE, V/Q (Pred + CycloP) 1.9, 11 0
5 58 F 2001 RVT, US (Pred + CycloP) 2.1, 7 0
6 68 F 2002 PE, CTPA (Pred + CycloP) 2.2, 5 0
7 79 M 2002 PE#, CTPA (Pred + MMF) 2.8, 9 + 2
8 72 M 2003 CVA# (Pred + MMF) 1.7, 14 + 3
9 50 M 2003 DVT, US (Pred + CycloP) 1.5, 12 - 2
10 64 F 2004 DVT, US (Pred + CycloP) 2.2, 5 - 0.5
11 42 M 2005 PE, CTPA (spontaneous remission) 2.0, 12 0
12 22 M 2005 PE, CTPA (Pred + CsA) 1.2, 12 0
13 39 M 2005 PE#, CTPA (Pred + CycloP) 1.9, 11 + 1
14 61 M 2007 PE#, CTPA (Pred + CycloP) 1.6, 12 + 1
*14/15 had complete data sets.
PE, pulmonary embolism; V/Q, ventilation/perfusion; RVT, renal vein thrombosis; CTPA, computed tomographic pulmonary angiogram; CVA, cerebrovascular
accident; DVT, deep vein thrombosis; Pred, prednisolone; CsA, ciclosporin; CycloP, cyclophosphamide; MMF, mycophenolate mofetil.
All the patients who presented with TEs (patient 1, 2, 4, 5, 6, 9 – 12; 64%) were immediately anticoagulated on confirmation of the diagnosis of TE.
#Not on prophylactic anti-coagulation.
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66 ± 25 ml/min per 1.73 m2). Compared with IMN
patients who did not have an event, those who had a TE
had significantly greater 24 h-proteinuria (10.7 ± 3 vs.
7.1 ± 4 g, TE vs. no TE; p < 0.01), hypoalbuminemia
(1.9 ± 0.5 vs. 2.4 ± 0.4 g/dl, TE vs. no TE; p < 0.01) and
higher serum cholesterol (414 ± 124 vs. 317 ± 108 mg/dl,
TE vs. no TE; p < 0.05). On multivariable analysis, serum
albumin (odds ratio, 0.8; 95% confidence interval, CI:Table 2 Baseline characteristics and clinical data of patients w
renal biopsy*
Characteristic IMN patients*(n = 67) No Thromboem
Age (years) 58.3 ± 16.7 58.6 ± 16.7
Sex, male,n (%) 42 (63%) 38 (73%)
Ethnicity, n (%)
Caucasians 39 (59%) 31 (60%)
Afro-Carribeans 11 (16%) 09 (17%)
South Asians 09 (13%) 07 (14%)
Middle-East 08 (12%) 05 (09%)
Duration of follow-up (years) 7.2 ± 3 7.1 ± 3
s.creatinine (mg/dl) 1.24 ± 0.8 1.23 ± 0.7
s.albumin (g/dl) 2.3 ± 0.4 2.4 ± 0.4
s.cholesterol (mg/dl) 336 ± 128 317 ± 108
eGFR (ml/min per 1.73 m2) 65 ± 27 66 ± 25
Proteinuria (g/24 h) 7.9 ± 3.5 7.1 ± 4
Immuno-suppresion 49 (73.1%) 35 (66%)
* IMN patients with complete data (n = 67/78, 85.8%): IMN patients with no TE and0.7 – 0.96, p = 0.01) and 24 h-proteinuria (odds ratio,
1.3; 95% CI: 1.05 – 1.58, p = 0.01) were found to be in-
dependent predictors of TEs (Table 3). A test of full
model against a constant only model was statistically
significant, indicating predictors as a set reliably distin-
guished between patients with TEs and no TEs (chi
square = 16.98, p < 0.000 with degrees of freedom= 2).
Because no TEs occurred after 6 months of diagnosis
of IMN, we next looked at proteinuria and serumith idiopathic membranous nephropathy at the time of
bolic events (n = 53) Thromboembolic events (n = 14) P-value






7.8 ± 3.2 NS
1.28 ± 0.8 NS
1.9 ± 0.5 < 0.01
414 ± 124 0.01
62 ± 29 NS
10.7 ± 3 <0.01
12 (86%)
with TE, 84% (n = 53/63) and 93% (n = 14/15); respectively.
Table 3 Adjusted* Odds Ratio for Risk of
Thromboembolic Events in patients with idiopathic
membranous nephropathy
Variable Odds Ratio (95% CI) P- value
s.albumin (per g/dl) 0.8 (0.7 – 0.96) 0.01
24 h-proteinuria (per g/24 h) 1.3 (1.05 - 1.58) 0.01
Male 0.7 – 2.1 NS
s.cholesterol 0.86 – 1.5 NS
s.creatinine 0.79 – 3 NS
* Adjusted for age, sex, serum cholesterol and serum creatinine.
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Overall, all patients had either partially or completely re-
mitted, with none of the patients left with nephrotic
range proteinuria. There was no significant difference
between the mean serum abumin (3.72 ± 0.06 g/L vs.
3.65 ± 0.08 g/L; no TE vs. TE group; respectively) nor
24 h mean proteinuria (0.95 ± 0.17 g vs. 1.09 ± 0.29 g; no
TE vs. TE group; respectively) at 6 months between the
two groups. Two thromboembolic events occurred in
the secondary MN group both of which were associated
with systemic lupus erythematosus.
Discussion
To the best of our knowledge, this is the first study that
describes the timing of the TEs relative to the diagnosis
and (ii) the risk factors (including disease activity) for
TEs in patients with idiopathic membranous nephropa-
thy. We found that the majority of TE events occurred
before or at diagnosis of IMN and 7.4% suffered a TE
over the next 6 months after the IMN diagnosis was
established. No events occurred after 6 months of IMN
diagnosis in our study population. Moreover, in patients
with TE events compared to those without TE events,
proteinuria and serum albumin are found to be inde-
pendent risk factors for thromboembolic events in adult
IMN patients.
In our study, 19% of IMN patients (when analysed
cross-sectionally) had at one time in their disease course
a TE (either prior to or directly after IMN diagnosis).
Our finding suggests that the incidence rate of first
thromboembolic event in IMN patients is high when
compared to the available rates in general population
(0.3 per 100 person-years) and in patients with lupus
(1 per 100 person-years) [11,19]. It is comparable to
patients with Wegener’s granulomatosis (7 per 100 per-
son-years) and people who had a previous deep vein
thrombosis (7 per 100 person-years) [20,21]. The inci-
dence of TE in our cohort (7.6% over 6 months) is less
than the incidence reported by Bellomo and colleagues
in their MN cohort (16.9%). This could be partly
explained by the difference in the proportion of im-
munosuppressed patients to treat the nephrotic rangeproteinuria (25% of their patients with TE were im-
munosuppressed versus 100% of our patients with TE).
However, how the incidence was measured was not
mentioned in the latter study. A recent retrospective co-
hort study confirmed high absolute risk (approximately
eight times) of venous TEs in patients with nephrotic
range proteinuria and in addition, found a high annual
incidence of 1.40 among the MN patients with nephrotic
syndrome [4]. However, the study was not specifically
aimed at studying MN patient and included patients
with as diverse as patients with diabetic nephropathy
(28%) and nephrotic syndrome not otherwise specified
(46%). In both these studies, no information was availa-
ble on the underlying etiology of MN (i.e. primary vs
secondary), the relation of TEs to the timing of diagnosis
and disease activity and the predictors specific to IMN
patients.
Another question is why IMN patients are at an exag-
gerated risk of TEs when compared to patients with
other causes of similar profound non-selective nephrotic
range proteinuria such as FSGS or amyloid nephropathy.
It is tempting to hypothesize that perhaps the underling
trigger unique to IMN pathology render IMN patients at
higher risk of TEs. We found that all the TEs occurred
when the IMN was active. This suggests that the exag-
gerated risk of TEs in IMN patients is due to the under-
lying nephrotic syndrome.
In our study, pulmonary embolism was the most com-
mon thromboembolic event followed by deep vein
thrombosis. Our findings are in line with those reported
by Bellomo et al. A recent review of the coding data
from the discharged patients in the United States with
nephrotic syndrome found deep vein thrombosis in 1.5%
and PE in 0.5% and less than 0.5% had renal vein throm-
bosis [22]. In contrast, the studies conducted in late
1970s and early 1980s reported renal vein thrombosis as
the commonly encountered TE in MN patients [5-7,14].
This discrepancy may be explained by the fact that the
latter studies evaluated patients with nephrotic syn-
drome with renal venography to specifically determine
renal vein thrombosis.
Bellomo et al. found that the baseline serum albumin
and 24-h proteinuria, between the patients who suffered
a TE and those with no TE, were similar, though signifi-
cantly greater proportion of patients in the TE group
had nephrotic syndrome with albumin < 2.5 g/l. Based
on this observation, it was concluded that the presence
of the nephrotic syndrome and of a low serum albumin
(< 2.5 g/l) at presentation was associated with a signifi-
cantly greater risk of TE. Our study, for the first time,
has formally quantified the increased odds of TE asso-
ciated with lower serum albumin in adult IMN patients.
In addition, we also find that the magnitude of protein-
uria should be taken into account while assessing the
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greater than 10 g/day could be regarded as an indepen-
dent risk factor for thromboembolic events in patients
with IMN, irrespective of the serum albumin. This is not
surprising as one of the major mechanisms of thrombo-
philia in IMN patients is urinary loss of critical proteins
involved in coagulation including plasminogen, factors
IX, X and XII, and antithrombin III [14-16]. None of
our patients after 6 months of diagnosis had thrombo-
embolic events. One may therefore consider primary
thromboprophylaxis in the first six months following the
diagnosis of IMN especially in patients with significant
proteinuria (>10 g/day) and/or serum albumin (<20 g/dl).
Similar to our finding, the Midwest Pediatric Nephrology
Consortium Study (MWPNC study), found proteinuria
(p < 0.0001) as a significant independent risk factor of TE
in children with nephrotic syndrome [23]. The possible
link between microalbuminuria or proteinuria and the
risk of thromboembolic events have also been demons-
trated in the general population, in patients with atrial
fibrillation and in a cohort of hospitalized patients with
nephrotic syndrome who underwent imaging study for
TE [22,24-26].
Our study has all limitations that are inherent to ob-
servational studies. These include confounding by other
factors, which we have not measured. We had clear
diagnostic criteria so exposure or outcome misclassifica-
tion is unlikely. Our study lacks the detailed thrombo-
philia profile of the study population. In spite of the
above limitations, these results may have important
implications for clinical care of patients with IMN. Our
study provides vital information that may help in, firstly,
regarding the timing and the possible duration of
prophylactic anti-coagulation; secondly, about the pa-
tient number that could benefit from prophylactic anti-
coagulation; and thirdly, identification of proteinuria, as
an independent risk factor that may aid in better risk
assessment of such patients. In addition, the demogra-
phic characteristics of our patient population, including
patients from various ethnicities, support the generali-
zability of our findings to IMN patients elsewhere. The
results of our study may help in appropriate power cal-
culation of future prospective randomized controlled
trials in IMN patients with regards to thromboprophy-
laxis. Furthermore, the findings highlight the importance
of urine dipstick testing in patients with TE, as TE could
be a presenting clinical feature of nephrotic syndrome,
in particular membranous nephropathy. Further pros-
pective large studies are required to confirm the findings
of our study.
Conclusions
The severity of proteinuria, in addition to hypoalbumi-
nemia, should be taken into account while evaluatingthe risk for thromboembolic events in patients with
IMN. The risk is greatest in the first six months of diag-
nosis. Urine dipstick analysis should be performed as a
part of initial evaluation of all patients presenting with
thromboembolic events. These results have important
implications for clinical care of patients with IMN,
particularly with regards to initiation and duration of
prophylactic anticoagulation.
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